Vincerx Pharma (NASDAQ:VINC) Shares Scheduled to Reverse Split on Tuesday, January 28th

Vincerx Pharma, Inc. (NASDAQ:VINC)’s stock is scheduled to reverse split on Tuesday, January 28th. The 1-20 reverse split was announced on Thursday, January 23rd. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, January 27th.

Vincerx Pharma Price Performance

Shares of VINC traded down $0.03 during trading hours on Friday, hitting $0.10. 7,380,350 shares of the company were exchanged, compared to its average volume of 4,778,677. The company has a market capitalization of $3.50 million, a PE ratio of -0.10 and a beta of 1.48. The firm has a fifty day simple moving average of $0.22 and a 200-day simple moving average of $0.46. Vincerx Pharma has a one year low of $0.10 and a one year high of $9.37.

Wall Street Analyst Weigh In

Separately, Leerink Partners decreased their price target on Vincerx Pharma from $4.00 to $2.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th.

Hedge Funds Weigh In On Vincerx Pharma

An institutional investor recently bought a new position in Vincerx Pharma stock. Armistice Capital LLC bought a new stake in Vincerx Pharma, Inc. (NASDAQ:VINC) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 1,988,000 shares of the company’s stock, valued at approximately $1,610,000. Armistice Capital LLC owned 6.70% of Vincerx Pharma at the end of the most recent reporting period. 44.02% of the stock is owned by institutional investors.

About Vincerx Pharma

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.